Topics

Companies Related to "tuberculosis vaccine shows efficacy over three years negative" [Most Relevant Company Matches] RSS

08:30 EST 10th December 2019 | BioPortfolio

Here are the most relevant search results for "tuberculosis vaccine shows efficacy over three years negative" found in our extensive corporate database of over 50,000 company records.

Showing "tuberculosis vaccine shows efficacy over three years negative" Companies 1–25 of 4,600+

Relevant

Why We Vaccinate

Why We Vaccinate (WWV) is a not-for-profit coalition on a mission to advocate for pro-health legislation, improve immunization conversations between doctors and patients and respond to anti-vaccine misinformation. The coalition aims to change the immunization discussion by clearly communicating the 250 years of research proving the safety and efficacy of vaccines. By sharing vaccine facts with ke...


Swiss Vaccine Research Institute

The SVRI is a partnership of five research institutes in Switzerland. The SVRI was created in 2007 in Lausanne and is supported by the Swiss Secretariat of Education and Research. Its primary objective is to develop effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer. SVRI plays an instrument...

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Ad...


Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine developm...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...

SBL VACCIN AB

SBL Vaccines (SBL) is a Swedish registered company with in-house research, development and manufacturing capabilities, marketing our specialist vaccines internationally. A complete vaccine portfolio sourced from global vaccine companies is marketed in the Nordic region by our distribution division based in Stockholm.Our core product Dukoral is an oral vaccine that protects against cholera and trav...

TruMed

TruMed® Systems, a medical technology company developing innovative point-of-care supply management systems for healthcare professionals, today announced the commercial availability of the AccuVax® Vaccine Management Systems. TruMed Systems' mission is to improve healthcare practitioners’ total vaccine outcomes by creating point-of-care supply m...

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer. Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination. HspC...

Tres Mares Group

Miler Lagos was born in Bogota in 1973. He has had solo shows in the U.S., Puerto Rico, Mexico, Bogota, and group shows all over Latin America, UK, France and Germany.

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

SBC – Schweitzer Biotech Corporation

SBC cooperate with academia, government institutions and industry to explore opportunities and develop superior and patentable technologies.SBC technologies shall contribute to increased productivity, stability and efficacy in vaccine production and applications - giving our customers cost advantages thus increased competitiveness.Proper use of vaccines is an important tool in quality management. ...

Sabin Vaccine Institute

Sabin Vaccine Institute is a 501(c)(3) non-profit organization dedicated to reducing human suffering from infectious and neglected diseases. Through its efforts in vaccine research, development and advocacy, Sabin works to provide greater access to vaccines and essential medicines for millions mired in pain, poverty and despair. Founded in 1993 in honor of Dr. Albert B. Sabin, discoverer of the or...

Inviragen, Inc. and PharmaJet, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Hawaii Biotech, Inc.

Hawaii Biotech, Inc. is a privately held biopharmaceutical company focused on vaccine research and development. The company is targeting first world vaccines with potentially large markets and attractive margins: a West Nile vaccine targeting the U.S. and Canada; and a dengue fever vaccine for travelers from first world countries to dengue endemic areas. The Company’s vaccine technology was feat...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

TB Biosciences, Inc.

TB Biosciences, Inc. is an early stage development medical diagnostics company founded in June 2013 to develop a rapid point-of-care tuberculosis test that meets performance standards around the world. The goal of TB Biosciences is to commercialize a simple to operate and use tuberculosis test that replaces the 125 year old sputum smear test. The Company i...

KXBEVENTS

KXBEVENTS was founded in 2007 and specializes in promoting, producing and recording stand-up comedy shows, corporate events and fundraisers. Their television shows are broadcast on Channel 19 Time Warner Cable San Diego every Thursday night at 10:30 p.m. For additional information about KXBEVENTS, contact Klaus Biegler, producer, at info@kxbevents.com.

Achaogen, Inc.

Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resistant, Gram-negative bacteria. The company’s pipeline includes ACHN-490, an aminoglycoside currently being evaluated in a Phase 2 clinical study for the treatment of complicated ...

TruMed Systems, Inc.

TruMed Systems, a medical technology company, develops the innovative AccuVax® Vaccine Management System for healthcare professionals. AccuVax is a purpose-built vaccine management solution that safeguards vaccine viability, frees staff time, protects vaccine investment, and maximizes patient safety so that providers can focus on care delivery. AccuVax is ...

Vaxin Inc.

Vaxin Inc. is a clinical stage biotechnology company, founded in December 1997 with facilities in Rockville, MD and Birmingham, AL, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technol...

Tballiance

We are building a portfolio of promising drug candidates and forging innovative partnerships in order to deliver a new anti-tuberculosis drug in a decade.A not-for-profit enterprise, we enlist the best practices, science and resources of the private and public sectors the world over to meet this urgent health need.Our mission is to ensure equitable access to a faster tuberculosis cure that will ad...

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...

Biotech Synergy

Biotech Synergy has secured in San Diego the necessary competences to bring this promising multi epitope cancer vaccine to latest stage development. Contrary to Dendreon individualized vaccine, EP-2101 is made of 10 peptides and is an off the shelf readily available vaccine for the HLA-A2 population, which represents 45% of the global NSCLC patients (100,0...

GeneMax

GeneMax develops innovative immunotherapies in the fields of oncology and infectious disease. Our patented technology restores or increases antigen processing and antigen specific immune responses. GeneMax has demonstrated preclinical efficacy in animal models of lung cancer and melanoma as well as proof of principle for infectious disease pathogens.GeneMax’s program also includes developing a t...

Variation Biotechnologies, Inc.

VBI is an emerging leader in the innovative formulation, delivery and development of vaccines. The Company’s powerful, proprietary technology platforms enable thermostable IM and thermostable oral vaccine delivery, creating improved dose equivalent and the potential for dose sparing and adjuvanted vaccines, extending vaccine reach and coverage in established...


More From BioPortfolio on "tuberculosis vaccine shows efficacy over three years negative"

Quick Search

Corporate Database Quicklinks